Real-World Outcomes in Patients With Relapsed-Refractory Multiple Myeloma (RRMM) With Prior Proteasome Inhibitor and Lenalidomide Exposure in Sweden

被引:0
作者
Luong, Vincent [1 ,2 ]
Kashif, Muhammad [1 ]
Uttervall, Katarina [1 ,2 ]
Bohlin, Anna [1 ]
Fernstrom, Annette Oster [1 ]
Qu, Ying [3 ]
Lee, Seina [4 ]
Mendes, Joao [5 ]
Van Hoorenbeeck, Sandra [6 ]
Franck, Eva Hellqvist [3 ]
He, Jianming [7 ]
Alici, Evren [1 ,2 ]
Lund, Johan [1 ,2 ]
机构
[1] Karolinska Inst, Ctr Hematol & Regenerat Med, Dept Med, Solna, Sweden
[2] Karolinska Univ Hosp, Dept Hematol, Solna, Sweden
[3] Janssen Cilag AB, Stockholm, Sweden
[4] Janssen Res & Dev, Raritan, NJ USA
[5] Janssen Cilag Farmaceut, Sao Paulo, Brazil
[6] Janssen Cilag NV, Beerse, Belgium
[7] Janssen Global Serv LLC, Raritan, NJ USA
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
P-407
引用
收藏
页码:S269 / S270
页数:2
相关论文
empty
未找到相关数据